


DarioHealth | Company Overview

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company that provides mobile health and big data solutions for a revolutionary approach to managing chronic diseases. DarioHealth takes the best of both worlds – the world of the wearable device market, which is projected to reach \$51.6 B and the health monitoring market which is climbing toward \$30 B. The Company’s first product serves the large and growing diabetes market. The Dario Blood Glucose Monitoring System is an award-winning glucose management system that includes an all-in-one smart blood glucose management system device, a mobile app and unlimited test strips. The system uses cloud-based big data management to help patients and their doctors optimize patient care. Dario’s user-centric diabetes system gets high marks from users, creates healthcare savings of \$80-\$100 per patient per month, and improves the health of users by reducing HbA1C, a key measure of diabetes. Dario’s flagship diabetes product has regulatory approval and is marketed in several countries including the U.S., driving high growth recurring revenues.



Digital Platform Revolutionizes Chronic Disease Management

Dario’s proprietary, patented digital platform harnesses big data to personalize and optimize disease management, resulting in better outcomes for patients and reduced healthcare costs. Dario’s revolutionary technology moves healthcare from periodic data to continuous data and from general treatment to personalized treatment by integrating artificial intelligence (AI) and machine learning (ML) to improve health. The Company’s user-centric, data driven platform is highly scalable and ready to launch products for numerous disease indications.

Diabetes Product Launched in 7 Countries to Serve 48.5 M People

The multiple award-winning Dario Blood Glucose Monitoring System has received regulatory approval and launched in the U.S., UK, Australia, Canada, Italy, Netherlands and Germany, representing 48.5 million people with diabetes. The cost of Dario’s product is fully reimbursed for users in 5 of these countries. Dario continues to expand its market reach. Globally, 425 million people are living with diabetes.

Growth Strategy: More Users & More Revenue Per User

Dario charges on average \$25 per month for its Dario Blood Glucose Monitoring System device and consumables. The Company is increasing the number of users by expanding its diabetes product offering into providing services and selling through additional channels including insurance providers, clinics and employers. Dario also plans to launch products for other chronic conditions. To increase revenue per user, in the near-term Dario plans to offer a disease management coaching platform for an additional average fee of \$25 per month per user as well as in-app premium and membership offerings. Reaching 1% penetration rate in the U.S. diabetes market would result in \$160 million in annual revenues for Dario.

Equity Overview

as of May 12, 2018

Nasdaq Ticker:	DRIO
Stock Price:	\$1.82
52-Week Range:	\$1.32 - \$3.64
Avg. volume (3 months):	165,000
Shares Outstanding:	16.74M
Market Cap:	\$30.5M

Financial Highlights

- Subscription business model yields highly recurring and visible revenues
- 62% of users under recurring plans
- Service is becoming an increasing contributor to revenues
- Diversified revenue streams
- Scalable model with meaningful operating leverage
- Recently launched B2B (employers) strategy provides incremental market opportunity and growth



Erez Raphael, Chairman & CEO
DarioHealth Corp.
142 W 57th Street, 8th Floor
New York, NY 10019
USA

partnershipgroup@dariohealth.com
www.dariohealth.com




**WESTWICKE
PARTNERS**

Investor Relations
Westwicke Partners
Tel: 1-443-213-0500
Dario@Westwicke.com
www.westwickepartners.com

DarioHealth | Company Overview

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company that provides mobile health and big data solutions for a revolutionary approach to managing chronic diseases. DarioHealth takes the best of both worlds – the world of the wearable device market, which is projected to reach \$51.6 B and the health monitoring market which is climbing toward \$30 B. The Company's first product serves the large and growing diabetes market. The Dario Blood Glucose Monitoring System is an award-winning glucose management system that includes an all-in-one smart blood glucose management system device, a mobile app and unlimited test strips. The system uses cloud-based big data management to help patients and their doctors optimize patient care. Dario's user-centric diabetes system gets high marks from users, creates healthcare savings of \$80-\$100 per patient per month, and improves the health of users by reducing HbA1C, a key measure of diabetes. Dario's flagship diabetes product has regulatory approval and is marketed in several countries including the U.S., driving high growth recurring revenues.

Strong Revenue Growth Reflects Rapid Market Adoption (In Thousands)



Digital Platform Revolutionizes Chronic Disease Management

Dario's proprietary, patented digital platform harnesses big data to personalize and optimize disease management, resulting in better outcomes for patients and reduced healthcare costs. Dario's revolutionary technology moves healthcare from periodic data to continuous data and from general treatment to personalized treatment by integrating artificial intelligence (AI) and machine learning (ML) to improve health. The Company's user-centric, data driven platform is highly scalable and ready to launch products for numerous disease indications.

Diabetes Product Launched in 7 Countries to Serve 48.5 M People

The multiple award-winning Dario Blood Glucose Monitoring System has received regulatory approval and launched in the U.S., UK, Australia, Canada, Italy, Netherlands and Germany, representing 48.5 million people with diabetes. The cost of Dario's product is fully reimbursed for users in 5 of these countries. Dario continues to expand its market reach. Globally, 425 million people are living with diabetes.

Growth Strategy: More Users & More Revenue Per User

Dario charges on average \$25 per month for its Dario Blood Glucose Monitoring System device and consumables. The Company is increasing the number of users by expanding its diabetes product offering into providing services and selling through additional channels including insurance providers, clinics and employers. Dario also plans to launch products for other chronic conditions. To increase revenue per user, in the near-term Dario plans to offer a disease management coaching platform for an additional average fee of \$25 per month per user as well as in-app premium and membership offerings. Reaching 1% penetration rate in the U.S. diabetes market would result in \$160 million in annual revenues for Dario.

Equity Overview

as of May 12, 2018

Nasdaq Ticker:	DRIO
Stock Price:	\$1.82
52-Week Range:	\$1.32 - \$3.64
Avg. volume (3 months)	165,000
Shares Outstanding:	16.74M
Market Cap:	\$30.5M

Financial Highlights

- Subscription business model yields highly recurring and visible revenues
- 62% of users under recurring plans
- Service is becoming an increasing contributor to revenues
- Diversified revenue streams
- Scalable model with meaningful operating leverage
- Recently launched B2B (employers) strategy provides incremental market opportunity and growth



Erez Raphael, Chairman & CEO
DarioHealth Corp.
142 W 57th Street, 8th Floor
New York, NY 10019
USA

partnershipgroup@dariohealth.com
www.dariohealth.com



WESTWICKE
PARTNERS

Investor Relations
Westwicke Partners
Tel: 1-443-213-0500
Dario@Westwicke.com
www.westwickepartners.com